These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37608405)

  • 1. [Radiotherapy].
    Nishibuchi I
    Gan To Kagaku Ryoho; 2023 Aug; 50(8):845-848. PubMed ID: 37608405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spanish Society of Radiation Oncology clinical guidelines for stereotactic body radiation therapy in lymph node oligometastases.
    Conde-Moreno AJ; Lopez-Guerra JL; Macias VA; Vázquez de la Torre ML; Samper Ots P; San José-Maderuelo S; Pastor Peidro J; López-Torrecilla J; Expósito-Hernández J
    Clin Transl Oncol; 2016 Apr; 18(4):342-51. PubMed ID: 26329294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR).
    Franzese C; Vernier V; Franceschini D; Comito T; Navarria P; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Marini B; Galdieri C; Mancosu P; Tomatis S; Scorsetti M
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10495-10503. PubMed ID: 37280407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
    Eufemon Cereno R; Mou B; Baker S; Chng N; Arbour G; Bergman A; Liu M; Schellenberg D; Matthews Q; Huang V; Mestrovic A; Hyde D; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Jiang W; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson RA
    Radiother Oncol; 2023 May; 182():109576. PubMed ID: 36822355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial.
    Trovo M; Furlan C; Polesel J; Fiorica F; Arcangeli S; Giaj-Levra N; Alongi F; Del Conte A; Militello L; Muraro E; Martorelli D; Spazzapan S; Berretta M
    Radiother Oncol; 2018 Jan; 126(1):177-180. PubMed ID: 28943046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
    Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
    BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic radiotherapy in oligometastatic cancer.
    Kennedy TAC; Corkum MT; Louie AV
    Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?
    Franzese C; Badalamenti M; Comito T; Franceschini D; Clerici E; Navarria P; Loi M; D'agostino G; Baldaccini D; Chiola I; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
    Radiother Oncol; 2020 Sep; 150():184-190. PubMed ID: 32593644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.
    Kent CL; McDuff SGR; Salama JK
    Ann Palliat Med; 2021 May; 10(5):5954-5968. PubMed ID: 32921069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
    Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
    Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligometastases: history of a hypothesis.
    Milano MT; Biswas T; Simone CB; Lo SS
    Ann Palliat Med; 2021 May; 10(5):5923-5930. PubMed ID: 32279519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of immunotherapy in combination with oligometastasis-directed therapy: a narrative review.
    Turchan WT; Chmura SJ
    Ann Palliat Med; 2021 May; 10(5):6028-6044. PubMed ID: 33440982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial.
    Zhao X; Wang T; Ye Y; Li J; Gao X; Zhang H
    BMJ Open; 2022 Sep; 12(9):e051371. PubMed ID: 36180115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.
    Olson R; Mathews L; Liu M; Schellenberg D; Mou B; Berrang T; Harrow S; Correa RJM; Bhat V; Pai H; Mohamed I; Miller S; Schneiders F; Laba J; Wilke D; Senthi S; Louie AV; Swaminath A; Chalmers A; Gaede S; Warner A; de Gruijl TD; Allan A; Palma DA
    BMC Cancer; 2020 May; 20(1):380. PubMed ID: 32370765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of the medical-physics-related verification system for radiotherapy multicenter clinical trials by the Medical Physics Working Group in the Japan Clinical Oncology Group-Radiation Therapy Study Group.
    Nishio T; Nakamura M; Okamoto H; Kito S; Minemura T; Ozawa S; Kumazaki Y; Ishikawa M; Tohyama N; Kurooka M; Nakashima T; Shimizu H; Suzuki R; Ishikura S; Nishimura Y
    J Radiat Res; 2020 Nov; 61(6):999-1008. PubMed ID: 32989445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of radiotherapy in the management of brain oligometastases.
    Antoni D; Mesny E; El Kabbaj O; Josset S; Noël G; Biau J; Feuvret L; Latorzeff I
    Cancer Radiother; 2024 Feb; 28(1):103-110. PubMed ID: 37802747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic Body Radiotherapy - Current Indications.
    Burkoň P; Slavik M; Kazda T; Pospíšil P; Prochazka T; Vrzal M; Šlampa P
    Klin Onkol; 2019; 32(1):10-24. PubMed ID: 30894002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy in Treating Brain Metastases.
    Scarpelli DB; Fatheree S; Jaboin JJ
    Pract Radiat Oncol; 2021; 11(6):488-490. PubMed ID: 34052537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Evolution (and Future) of Stereotactic Body Radiotherapy in the Treatment of Oligometastatic Disease.
    Onderdonk BE; Gutiontov SI; Chmura SJ
    Hematol Oncol Clin North Am; 2020 Feb; 34(1):307-320. PubMed ID: 31739951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic Radiation for Oligometastatic and Oligoprogressive Stage IV Breast Cancer: A Case-Based Review.
    Freedman GM; Jones JA; Taunk NK
    Curr Oncol; 2023 Feb; 30(2):2510-2523. PubMed ID: 36826153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.